RT Journal Article SR Electronic T1 Fitness barriers to spread of colistin-resistant Klebsiella pneumoniae overcome by establishing niche in patient population with elevated colistin use JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.06.11.21258758 DO 10.1101/2021.06.11.21258758 A1 Zena Lapp A1 Jennifer H Han A1 Divya Choudhary A1 Stuart Castaneda A1 Ali Pirani A1 Kevin Alby A1 Pam Tolomeo A1 Ellie JC Goldstein A1 Sean Muldoon A1 Ebbing Lautenbach A1 Evan S Snitkin YR 2021 UL http://medrxiv.org/content/early/2021/06/13/2021.06.11.21258758.abstract AB To combat antibiotic resistance, it is critical to improve our understanding of how new resistant strains emerge and spread. An antibiotic resistance threat of critical priority is the epidemic ST258 strain of carbapenem-resistant Klebsiella pneumoniae (CRKP). Here, we studied the spread of resistance among ST258 to an antibiotic of last resort, colistin, by tracking its evolution across 21 U.S. long-term acute care hospitals over the course of a year. Phylogenetic analysis suggested that a significant cost was associated with colistin resistance in most cases, as resistance emergence was common but resistance variants were rarely transmitted. The high cost of resistance was further supported by the observation that several of the resistance variants that were transmitted had acquired secondary variants that reverted the strain to colistin susceptibility. The exceptions to the general pattern of instability associated with colistin resistance were two large clusters of resistant strains in one ST258 clade II sublineage (clade IIB) present across 11 of the 12 sampled Southern California hospitals. Quantification of transmission fitness in the healthcare environment using time-scaled haplotypic density indicated that while resistant isolates from other clades were less fit than their susceptible counterparts, clade IIB resistant isolates were more fit. Overlaying patient clinical data suggested that the increased fitness of colistin-resistant clade IIB isolates is in part driven by a lineage defining variant that increased clade IIB’s association with patient subpopulations who were more likely to be treated with colistin. These results show that a favorable genetic background and sustained selective pressure led to the emergence and spread of a colistin-resistant ST258 sublineage across a regional healthcare network. More broadly, these findings highlight the utility of integrating pathogen genomic and corresponding clinical data from regional healthcare networks to detect and understand the origin and dissemination of antibiotic resistance threats.Competing Interest StatementJ.H.H. is currently an employee of, and holds shares in, the GSK group of companies.Funding StatementThis research was supported by a CDC Cooperative Agreement FOA no. CK16-004-Epicenters for the Prevention of Healthcare Associated Infections and the National Institutes of Health R01 AI139240-01 and 1R01 AI148259-01. Z.L. received support from the National Science Foundation Graduate Research Fellowship Program under grant no. DGE 1256260. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation. The funding bodies had no role in the design of the study or collection, analysis, and interpretation of data, or in writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No new data used. The original study was reviewed and approved by the Institutional Review Board of the University of Pennsylvania with a waiver of informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWhole-genome sequences from BioProject accession no. PRJNA415194 were used. Code and non-PHI data corresponding to the manuscript figures can be found on GitHub (https://github.com/Snitkin-Lab-Umich/ltach-crkp-colistin-ms). https://www.ncbi.nlm.nih.gov/bioproject?term=PRJNA415194 https://github.com/Snitkin-Lab-Umich/ltach-crkp-colistin-ms